TechMARK movers: Positive data for Renovo

Pharmaceuticals developer Renovo is the best performer in TechMARK following positive phase I data for a formulation of scar revision treatment Juvista. Broker Panmure Gordon believes that the results must be significant even if little detail has been published. The original formulation is going through phase III trials. Cash burn of £15m a year is forecast for the next three years. That would still elave Renovo with cash in the bank. Shares in Biocompatibles International continue to fall back in line with the share price of bidder BTG. The agreed bid is 1.6733 BTG shares and 10p in cash for each Biocompatibles share.Vislink has been hit by profit-taking since last Friday's sale of its oil and gas CCTV supplier Hernis. After the sale, cash will represent most of the market value of Vislink. FTSE TechMARK - RisersRenovo Group (RNVO) 39.00p +5.41%KCOM Group (KCOM) 53.00p +2.91%Asterand (ATD) 10.50p +2.44%Oxford Instruments (OXIG) 580.00p +1.49%Psion (PON) 96.00p +0.52%Alterian (ALN) 187.75p +0.40%Kofax (KFX) 276.00p +0.36%Promethean World (PRW) 78.00p +0.32%Corin Group (CRG) 48.25p 0.00%Triad Group (TRD) 18.00p 0.00%FTSE TechMARK - FallersImagination Technologies Group (IMG) 309.80p -3.91%Ceva Inc. (CVA) 1,250.00p -3.85%Biocompatibles International (BII) 375.00p -3.23%BTG (BGC) 218.90p -3.18%Pace (PIC) 187.40p -2.70%Antisoma (ASM) 6.00p -2.44%Sepura (SEPU) 41.50p -2.35%Anite (AIE) 55.25p -2.21%Vislink (VLK) 22.25p -2.20%E2V Technologies (E2V) 92.00p -2.13%Filtronic (FTC) 35.00p -2.10%